News >

Bekaii-Saab Shares Insight on Regorafenib Updates in mCRC

Brandon Scalea
Published: Wednesday, Aug 29, 2018

Tanios Bekaii-Saab, MD

Tanios Bekaii-Saab, MD
A weekly dose-escalation strategy of regorafenib (Stivarga) is clearly the new standard approach for the agent, as it was found to be superior than the previously average dose of 160 mg in patients with metastatic colorectal cancer (mCRC), said Tanios Bekaii-Saab, MD.

, Bekaii-Saab, a professor of medicine at Mayo Clinic, discussed the ReDOS and IMblaze370 with regorafenib trials in mCRC.

OncLive: Please provide some background to the ReDOS trial.

Bekaii-Saab: We wanted to test how effective the standard dose of 160 mg daily was for regorafenib. It worked for a few patients. For the majority of the patients—let's say 70% to 80%— they were not able to receive the full 160 mg. A lot of the toxicity started to appear in the first 2 to 3 weeks, and it also met its highest severity at that time. That certainly was one of the biggest challenges. Therefore, in the community, a lot of people started using their own schedule and started cutting down on the dose. Some people started with 80 mg and then made their way up to 120 mg. A lot of different alterations were made, but there were absolutely zero data saying that you could alter the dose and keep the same benefit.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication